| Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment |
Lorenzi |
2010 |
Pharma-Cog |
https://doi.org/10.1016/j.neurobiolaging.2010.04.036 |
Mild cognitive impairment, Conversion, Marker disease, Clinical trials, Enrichment
|
|
| Cortical sources of resting state electroencephalographic rhythms in Parkinson's disease related dementia and Alzheimer's disease |
Babiloni |
2011 |
Pharma-Cog |
https://doi.org/10.1016/j.clinph.2011.03.029 |
Parkinson’s disease (PD), Dementia, Resting-state electroencephalography (EEG), Low-resolution brain electromagnetic source tomography (LORETA), Brain rhythms, Alpha
|
|
| Disease Tracking Markers for Alzheimer’s Disease at the Prodromal (MCI) Stage |
Drago |
2011 |
Pharma-Cog |
https://doi.org/10.3233/jad-2011-0043 |
Alzheimer's disease, Mild cognitive impairment, neuropsychology, neuroimaging, diffusion tensor imaging, functional MRI, spectroscopy, positron emission tomography, EEG, cerebrospinal fluid
|
|
| Resting State Cortical Electroencephalographic Rhythms and White Matter Vascular Lesions in Subjects with Alzheimer's Disease: An Italian Multicenter Study |
Babiloni |
2011 |
Pharma-Cog |
https://doi.org/10.3233/jad-2011-101710 |
Alzheimer's disease, Alzheimer's disease neuroimaging initiative, amnesic mild c cognitive impairment, electroencephalographic rhythms, low resolution brain electromagnetic tomography, magnetic resonance imaging, resting state, white matter vascular lesion
|
|
| Stability of clinical condition in mild cognitive impairment is related to cortical sources of alpha rhythms: an electroencephalographic study |
Babiloni |
2011 |
Pharma-Cog |
https://doi.org/10.1002/hbm.21157 |
mild cognitive impairment, Alzheimer's disease, electroencephalography, alpha rhythms, low‐resolution brain electromagnetic tomography, cognitive decline
|
|
| The grey mouse lemur: A non-human primate model for ageing studies |
Languille |
2011 |
Pharma-Cog |
https://doi.org/10.1016/j.arr.2011.07.001 |
Ageing, Age-related disease, Lifespan, Microcebus murinus
|
|
| Animal Models of Alzheimer’s Disease and Drug Development |
Laurijssens |
2012 |
Pharma-Cog |
http://dx.doi.org/10.1016/j.ddtec.2012.04.001 |
alzheimer, treatments, hypotheses, patients, tools, animal, drugs
|
|
| Effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer’s disease patients |
Babiloni |
2012 |
Pharma-Cog |
https://doi.org/10.1016/j.clinph.2012.09.017 |
Electroencephalography (EEG), Drug treatments, Alzheimer’s disease
|
|
| Effects of Dietary Resveratrol on the Sleep-Wake Cycle in the Non-HumanPrimate Gray Mouse Lemur (Microcebus murinus) |
Pifferi |
2012 |
Pharma-Cog |
http://dx.doi.org/10.3109/07420528.2011.654019 |
Circadian rhythms, Electroencephalography, Metabolism, Microcebus, murinus, Resveratrol, Sleep
|
|
| Worldwide Alzheimer's disease neuroimaging initiative |
Carrillo |
2012 |
Pharma-Cog |
https://doi.org/10.1016/j.jalz.2012.04.007 |
Alzheimer's disease, neuroimaging, biomarkers
|
|
| A new paradigm for testing AD drugs – neuroimaging biomarkers as surrogate outcomes homologous in animals and humans |
Marizzoni |
2013 |
Pharma-Cog |
https://doi.org/10.1016/j.ddstr.2013.09.003 |
Memory, Alzheimer, Paradigm, neuroimaging
|
|
| Animal models of Alzheimer's disease and drug development |
Laurijssens |
2013 |
Pharma-Cog |
https://doi.org/10.1016/j.ddtec.2012.04.001 |
Animal models, alzheimer, drug development
|
|
| Brain morphometry reproducibility in multi-center 3T MRI studies: a comparison of cross-sectional and longitudinal segmentations |
Jovicich |
2013 |
Pharma-Cog |
https://doi.org/10.1016/j.neuroimage.2013.05.007 |
Brain morphometry; Multi-center; Multi-site MRI; Reliability; Reproducibility; Structural MRI
|
|
| Effects of pharmacological agents, sleep deprivation, hypoxia and transcranial magnetic stimulation on electroencephalographic rhythms in rodents |
Bablioni |
2013 |
Pharma-Cog |
https://doi.org/10.1016/j.clinph.2012.07.023 |
Electroencephalography, EEG, Neurodegeneration, Animal models, Drug treatments
|
|
| Evaluation of symptomatic drug effects in Alzheimer's disease: strategies for prediction of efficacy in humans |
Deguil |
2013 |
Pharma-Cog |
https://doi.org/10.1016/j.ddtec.2013.03.003 |
Alzheimer, Pharmacodynamic, biomarker, validationm, review
|
|
| Experimental sleep deprivation as a tool to test memory deficits in rodents |
Colavito |
2013 |
Pharma-Cog |
https://dx.doi.org/10.3389%2Ffnsys.2013.00106 |
Sleep, sleep-deprivation, memory, learning, cognitive impairment, Alzheimer's disease, rat, mouse
|
|
| Octodon degus: A Model for the Cognitive Impairment Associated with Alzheimer's Disease |
Tarragon |
2013 |
Pharma-Cog |
http://dx.doi.org/10.1111/cns.12125 |
Alzheimer disease, Amyloid beta-protein, Memory, Mild Cognitive Impairment
|
|
| Alzheimer disease, Amyloid beta-protein, Memory, Mild Cognitive Impairment |
Rahman |
2013 |
Pharma-Cog |
https://doi.org/10.1371/journal.pone.0064493 |
Sleep, Lemurs, Cognitive impairment, Learning, Alzheimer's disease, Primates, Spatial memory, Rodents,
|
|
| Alpha-Theta Effects Associated with Ageing during the Stroop Test |
Nombela |
2014 |
Pharma-Cog |
https://doi.org/10.1371/journal.pone.0095657 |
Stroop, Alpha, Theta, ageing
|
|
| Memantine prevents reference and working memory impairment caused by sleep deprivation in both young and aged Octodon degus |
Tarragon |
2014 |
Pharma-Cog |
https://doi.org/10.1016/j.neuropharm.2014.05.023 |
Alzheimer disease; Memantine; Memory; Octodon degus; Sleep deprivation.
|
|
| Multisite longitudinal reliability of tract-based spatial statistics in diffusion tensor imaging of healthy elderly subjects |
Jovicich |
2014 |
Pharma-Cog |
https://doi.org/10.1016/j.neuroimage.2014.06.075 |
Brain diffusion tensor imaging, Reproducibility, Reliability, Tract-based spatial statistics, Multi-center, Multi-site MRI
|
|
| Deficits of psychomotor and mnesic functions across aging in mouse lemur primates |
Languille |
2015 |
Pharma-Cog |
https://doi.org/10.3389/fnbeh.2014.00446 |
psychomotor, anxiety, working memory, spatial memory, recognition memory
|
|
| Longitudinal reproducibility of automatically segmented hippocampal subfields: A multisite European 3T study on healthy elderly |
Marizzoni |
2015 |
Pharma-Cog |
https://doi.org/10.1002/hbm.22859 |
Freesurfer; hippocampus; test-retest reproducibility; within session T1 averaging.
|
|
| On-Going Frontal Alpha Rhythms Are Dominant in Passive State and Desynchronize in Active State in Adult Gray Mouse Lemurs |
Infarinato |
2015 |
Pharma-Cog |
https://doi.org/10.1371/journal.pone.0143719 |
Lemur, Alpha, EEG, intervention
|
|
| P1-158: Spectral ongoing eeg markers of motor activity in mouse models in physiological aging and Alzheimer's disease |
Babiloni |
2015 |
Pharma-Cog |
https://doi.org/10.1016/j.jalz.2015.06.357 |
BEG. EEG, mice, Alzheimer
|
|
| Retinal aging in the diurnal Chilean rodent (Octodon degus): histological, ultrastructural and neurochemical alterations of the vertical information processing pathway |
Szabadfi |
2015 |
Pharma-Cog |
https://doi.org/10.3389/fncel.2015.00126 |
Octodon degus; aging; retina; rod bipolar cells; synaptic proteins; ultrastructure; vertical pathway.
|
|
| The Continuing Failure of Bexarotene in Alzheimer’s Disease Mice |
Balducci |
2015 |
Pharma-Cog |
https://doi.org/10.3233/jad-150029 |
Alzheimer’s disease; TASTPM mice; amyloid-β; apolipoprotein E; bexarotene; magnetic resonance imaging; memory; therapy.
|
|
| Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a ‘European ADNI study’ |
Galluzzi |
2016 |
Pharma-Cog |
https://doi.org/10.1111/joim.12482 |
biomarkers, electroencephalography, magnetic resonance imaging, mild cognitive impairment
|
|
| Free water elimination using a bi-tensor model improves test-retest reproducibility of diffusion tensor imaging indices in the brain |
Albi |
2016 |
Pharma-Cog |
https://doi.org/10.1002/hbm.23350 |
brain diffusion tensor imaging; free-water imaging; healthy elderly; longitudinal; multisite diffusion MRI; test-retest reproducibility.
|
|
| Impaired fasting blood glucose is associated to cognitive impairment and cerebral atrophy in middle-aged non-human primates |
Djelti |
2016 |
Pharma-Cog |
https://doi.org/10.18632/aging.101148 |
blood glucose, middle age, spatial memory performance, hippocampal/septal atrophy, spontaneous models, Microcebus murinus
|
|
| Longitudinal reproducibility of default-mode network connectivity in healthy elderly participants: A multicentric resting-state fMRI study |
Jovicich |
2016 |
Pharma-Cog |
https://doi.org/10.1016/j.neuroimage.2015.07.010 |
Default Mode Network; Functional connectivity; Multi-center; Multi-site MRI; Reproducibility.
|
|
| Test-retest reliability of the default mode network in a multi-centric fMRI study of healthy elderly: Effects of data-driven physiological noise correction techniques |
Marchitelli |
2016 |
Pharma-Cog |
https://doi.org/10.1002/hbm.23157 |
default mode network; independent component analysis; multisite; physiological noise correction; resting-state networks; task-free fMRI; test-retest reliability.
|
|
| The Effects of Physiological and Methodological Determinants on 18F-FDG Mouse Brain Imaging Exemplified in a Double Transgenic Alzheimer Model |
Deleye |
2016 |
Pharma-Cog |
https://doi.org/10.1177/1536012115624919 |
mouse, brain PET, SUV, 18F-FDG, Alzheimer
|
|
| Longitudinal Characterization of [18F]-FDG and [18F]-AV45 Uptake in the Double Transgenic TASTPM Mouse Model |
Waldron |
2017 |
Pharma-Cog |
http://doi.org/10.3233/jad-160760 |
Alzheimer’s disease, [18F]-AV45, [18F]-FDG, longitudinal, small animal imaging, transgenic mice
|
|
| On-going electroencephalographic rhythms related to cortical arousal in wild-type mice: the effect of aging |
Del Percio |
2017 |
Pharma-Cog |
https://doi.org/10.1016/j.neurobiolaging.2016.09.004 |
Electroencephalographic (EEG) rhythms, C57 wild-type (WT) mice, Awake active state, Awake passive state
|
|
| Adaptability and reproducibility of a memory disruption rTMS protocol in the PharmaCog IMI European project |
Martin-Trias |
2018 |
Pharma-Cog |
https://doi.org/10.1038/s41598-018-27502-1 |
TMS, rTMS, memory
|
|
| Effect of NAC treatment and physical activity on neuroinflammation in subchronic Parkinsonism; is physical activity essential? |
Gil-Martínez |
2018 |
Pharma-Cog |
https://doi.org/10.1186/s12974-018-1357-4 |
Parkinsonism, Neuroinflammation, Oxidative stress, Physical activity, Microglia, Astrocytes, S100b
|
|
| Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers |
Marizzoni |
2018 |
Pharma-Cog |
https://doi.org/10.3233/jad-180152 |
Alzheimer’s disease, biomarkers, clinical trial, magnetic resonance imaging, mild cognitive impairment, precision medicine
|
|
| Unexpected Exacerbation of Neuroinflammatory Response After a Combined Therapy in Old Parkinsonian Mice |
Gil-Martínez |
2018 |
Pharma-Cog |
https://doi.org/10.3389/fncel.2018.00451 |
Parkinsonism; aging; drug-repositioning; glia; neuroinflammation; oxidative stress.
|
|
| CSF cutoffs for MCI due to AD depend on APOEε4 carrier status |
Marizzoni |
2019 |
Pharma-Cog |
https://doi.org/10.1016/j.neurobiolaging.2019.12.019 |
Alzheimer's disease, Apolipoprotein E, Mild cognitive impairment, CSF cutoff, Disease progression
|
|
| Local Gastrointestinal Injury Exacerbates Inflammation and Dopaminergic Cell Death in Parkinsonian Mice |
Gil-Martínez |
2019 |
Pharma-Cog |
https://doi.org/10.1007/s12640-019-0010-z |
Parkinson’s disease, Ulcerative colitis, Systemic inflammation, Neurodegeneration
|
|
| One Step Forward Toward a Surrogate Endpoint for Clinical Trials of Alzheimer's Disease Drugs: The Results of PharmaCog WP5 (European ADNI) |
Frisoni |
2019 |
Pharma-Cog |
https://doi.org/10.3233/jad-190267 |
Alzheimer’s disease, biomarkers, clinical trial, magnetic resonance imaging, mild cognitive impairment, precision medicine
|
|
| Plasma Aβ42 as a Biomarker of Prodromal Alzheimer’s Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study |
Albani |
2019 |
Pharma-Cog |
https://doi.org/10.3233/jad-180321 |
Amnesic mild cognitive impairment; PharmaCog project; amyloid-beta peptide; biomarkers; clinical trial; clusterin; prodromal Alzheimer’s disease.
|
|
| Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease Using Topographical Biomarkers |
Jovicich |
2019 |
Pharma-Cog |
https://doi.org/10.3233/jad-180158 |
Alpha rhythms; PharmaCog project; amnesic mild cognitive impairment; biomarkers; clinical trial; electroencephalography; functional magnetic resonance imaging; oddball event-related potentials; prodromal Alzheimer’s disease; resting state.
|
|
| A Conformation Variant of p53 Combined with Machine Learning Identifies Alzheimer Disease in Preclinical and Prodromal Stages |
Abate |
2020 |
Pharma-Cog |
http://doi.org/10.3390/jpm11010014 |
blood-based biomarker, Alzheimer’s disease, machine learning, β-amyloid, conformation variant of p53
|
|
| Amygdalar nuclei and hippocampal subfields on MRI: Test-retest reliability of automated volumetry across different MRI sites and vendors |
Quattrini |
2020 |
Pharma-Cog |
https://doi.org/10.1016/j.neuroimage.2020.116932 |
Amygdalar nuclei, Hippocampal subfields, Multicenter MRI study, FreeSurfer, Reliability analysis
|
|
| Identification of differentially expressed genes profiles in a combined mouse model of Parkinsonism and colitis |
Gil-Martínez |
2020 |
Pharma-Cog |
https://doi.org/10.1038/s41598-020-69695-4 |
Parkinson, gene, mice
|
|
